ACTIVE

FARMACIE HENRI

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result-56,3 k €-175,1 %over 1 year
Gross margin11,3 k €-90,1 %over 1 year
Equity333,2 k €-14,5 %over 1 year
Workforce0,5 ETP-78,3 %over 1 year

Identity

Source · BCE/KBO

FARMACIE HENRI is a Private limited company incorporated in 1999. Its main activity is: Dispensing chemist in specialised stores. Its registered office is in Edegem. It employs on average 0,5 ETP workers (FTE).

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0467.212.772
Incorporation
04/11/1999
Legal form
Private limited company
Registered office
Prins Boudewijnlaan 272
2650 Edegem · FlandreSee on map
Contributed capital
20 000,00 €
Latest accounts
31/12/2025
Average workforce
0,5 ETP
Joint committees (2)
  • 313
  • 3130
Signals
Solid equityLow riskGood liquidityHealthy social debts

Financials

Source · NBB, 20 filings

Trend over 20 financial years

20252024202320222021
Income statement
Gross margin11,3 k €114,4 k €100,2 k €49,8 k €112,4 k €
EBITDA-30,6 k €9,6 k €38,2 k €14 k €5,1 k €
Operating result-45,3 k €-6,7 k €18,3 k €-3,5 k €-4,1 k €
Net result-56,3 k €-20,5 k €9,6 k €-6,5 k €650,6 €
Balance sheet
Equity333,2 k €389,6 k €410,1 k €400,5 k €627,8 k €
Total assets635,6 k €590,5 k €599,9 k €613,5 k €940,5 k €
Cash182,5 k €160,9 k €145,3 k €131,7 k €425,1 k €
Debts302,1 k €195,3 k €155,4 k €198 k €293,2 k €
Other
Workforce0,5 ETP2,3 ETP0,0 ETP0,5 ETP1,9 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 250 k€ and 500 k€
See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

2 active · 8 ended

Active mandates

SABU PHARMA

Director · since 01 mai 2025 · 1021.744.847

Represented by Christ SABUSHIMIKE

Active
MARIJKE VAN ZUNDERT CONSULTING

Director · since 22 novembre 2021 · 0727.575.125

Represented by Marijke Van Zundert

Active

Ended mandates

SABU PHARMA

Director · since 01 mai 2025 · 1021.744.847

Represented by Christ Sabushimike

Ended
MARIJKE VAN ZUNDERT CONSULTING

Director · since 22 novembre 2021 · 0727.575.125

Represented by Marijke VAN ZUNDERT

Ended
ROEL FIEY MANAGEMENT

Director · since 22 novembre 2021 · 0541.546.842

Represented by Roel FIEY

Ended
Linda Luijkx

Director

Ended

Full financial information

Source · NBB
202520242023202220212020
Type of accountAbridged modelAbridged modelAbridged modelAbridged modelAbridged modelAbridged model
Start of the financial year01/01/202501/01/202401/01/202301/01/202201/01/202101/01/2020
Closing of the financial year31/12/202531/12/202431/12/202331/12/202231/12/202131/12/2020
Length of the financial year12 months12 months12 months12 months12 months12 months
Filing date08/07/202626/05/202513/05/202423/05/202312/07/202220/07/2021
General meeting30/06/202610/05/202511/05/202413/05/202330/06/202229/06/2021
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 20 filings
ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202530/06/202608/07/2026DutchPDF
Abridged model31/12/202410/05/202526/05/2025DutchPDF
Abridged model31/12/202311/05/202413/05/2024DutchPDF
Abridged model31/12/202213/05/202323/05/2023DutchPDF
Abridged model31/12/202130/06/202212/07/2022DutchPDF
Abridged model31/12/202029/06/202120/07/2021DutchPDF
Abridged model31/12/201929/06/202024/07/2020DutchPDF
Micro model31/12/201829/06/201924/07/2019DutchPDF
Micro model31/12/201729/06/201825/07/2018DutchPDF
Abridged model31/12/201629/06/201720/07/2017DutchPDF
Abridged model31/12/201529/06/201626/07/2016DutchPDF
Abridged model31/12/201429/06/201528/07/2015DutchPDF
Abridged model31/12/201330/06/201430/07/2014DutchPDF
Abridged model31/12/201229/06/201329/07/2013DutchPDF
Abridged model31/12/201129/06/201224/07/2012DutchPDF
Abridged model31/12/201029/06/201126/07/2011DutchPDF
Abridged model31/12/200929/06/201028/07/2010DutchPDF
Abridged model31/12/200829/06/200924/07/2009DutchPDF
Abridged model31/12/200729/06/200825/07/2008DutchPDF
Abridged model31/12/200629/06/200725/07/2007DutchPDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 250 k€ and 500 k€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

2 active · 8 ended

Active mandates

SABU PHARMA

Director · since 01 mai 2025 · 1021.744.847

Represented by Christ SABUSHIMIKE

Active
MARIJKE VAN ZUNDERT CONSULTING

Director · since 22 novembre 2021 · 0727.575.125

Represented by Marijke Van Zundert

Active

Ended mandates

SABU PHARMA

Director · since 01 mai 2025 · 1021.744.847

Represented by Christ Sabushimike

Ended
MARIJKE VAN ZUNDERT CONSULTING

Director · since 22 novembre 2021 · 0727.575.125

Represented by Marijke VAN ZUNDERT

Ended
ROEL FIEY MANAGEMENT

Director · since 22 novembre 2021 · 0541.546.842

Represented by Roel FIEY

Ended
Linda Luijkx

Director

Ended

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Mandates06/06/2025
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Other24/12/2021
    DIVERSEN
    PDF
  • Mandates29/11/2021
    STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …) - WIJZIGING RECHTSVORM - BENAMING - ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates02/09/2021
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Restructuring09/03/2017
    BENAMING - MAATSCHAPPELIJKE ZETEL - KAPITAAL - AANDELEN - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …) - RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
    PDF
  • Restructuring02/01/2017
    RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 2025-56,3 k €↓
  2. 2024
    Annual accounts 2024-20,5 k €↓
  3. 2023
    Annual accounts 20239,6 k €↑
  4. 2022
    Annual accounts 2022-6,5 k €↓
  5. 2021
    Annual accounts 2021650,6 €↓
  6. 2021
    Name changeFARMACIE HENRI
  7. 2020
    Annual accounts 2020105,8 k €↑
  8. 2019
    Annual accounts 201988,3 k €↑
  9. 2018
    Annual accounts 201883,1 k €↑
  10. 2017
    Annual accounts 201764,1 k €↑
  11. 2016
    Annual accounts 201633,8 k €↑
  12. 2016
    Name changeAPOTHEEK LUIJKX
  13. 2015
    Annual accounts 201514,2 k €↑
  14. 2014
    Annual accounts 20143,6 k €↓
  15. 2013
    Annual accounts 201323,5 k €↑
  16. 2012
    Annual accounts 20127 k €↑
  17. 2011
    Annual accounts 2011-24,9 k €↓
  18. 2010
    Annual accounts 201023,1 k €↓
  19. 2009
    Annual accounts 200997,1 k €↑
  20. 2008
    Annual accounts 200837,1 k €↑
  21. 2007
    Annual accounts 200726,1 k €↓
  22. 2006
    Annual accounts 200627,6 k €
  23. 2006
    Name changeATS MANAGEMENT
  24. 04/11/1999
    IncorporationPrivate limited company